Glioblastoma Multiforme (GBM) bụ otu n'ime ọrịa kansa kachasị egbu egbu, ihe fọrọ nke nta ka ọ bụrụ ndị ọrịa niile na-enweta nlọghachi dịka ọkwa nlekọta ugbu a maka GBM a chọpụtara ọhụrụ. GBM (rGBM) na-apụtaghachi na-egosi na ọ na-adịru ihe na-erughị ọnwa 8 ma nwee obere nhọrọ ọgwụgwọ.
TX103 bụ ọgwụ ọgwụgwọ mkpụrụ ndụ CAR-T nke na-elekwasị anya na B7-H3, nke e mepụtara n'onwe ya ma nye ikike site na ikike ndị China na nke mba ụwa. E gosipụtara nsonaazụ mbụ nke ọgwụgwọ TX103 maka gliomas na-emegharị ugboro ugboro na Nzukọ Kwa Afọ nke American Society of Clinical Oncology (ASCO) na 2024.(NCT05241392).
Ụzọ: Nke a bụ ọmụmụ ihe e ji aka emeghe, nke nwere otu ogwe aka, nke a na-akpọ "3+3" dose-excessation na ọtụtụ doses. Ebumnuche bụ isi bụ inyocha nchekwa na dose kachasị mma a na-anabata. Ebumnuche nke abụọ gụnyere nsonaazụ ndụ, nzaghachi etuto ahụ, nzaghachi immunological, na paramita pharmacokinetic. E debanyere aha ndị ọrịa dị afọ 18 ruo 75 na nyocha onyonyo na ngosipụta B7-H3 >= 30% site na nyocha immunohistochemistry. E nyere TX103 intracavity na/ma ọ bụ intraventricular nye ndị ọrịa site na ebe nchekwa Ommaya. A na-enye TX103 kwa izu abụọ nye ndị ọrịa na usoro ọ bụla na ọkwa dose 1, 2, na 3 (20, 60, 150 nde sel, n'otu n'otu), yana usoro anọ dị ka otu usoro.
Nsonaazụ: N'etiti Machị 2022 na Jenụwarị 2024, ndị ọrịa 13 natara opekata mpe otu intracranial intracranial intracranial intracranial intracranial intracranial intracranial intracranial intracranial intracranial intracranial intracranial intracranial index, yana mmadụ 3, 4, na 6 nọ na ọkwa dose 1, 2, na 3, n'otu n'otu. Ọnụọgụ etiti nke usoro infusion bụ 4 (Min, Max 1,9). E tinyere ndị ọrịa niile na nyocha nchekwa, na-ekpughe enweghị nsí na-egbochi dose ma ọ bụ ọnwụ metụtara ọgwụgwọ CAR-T. Ndị ọrịa niile nwetara opekata mpe otu ihe ọjọọ (AE), yana AEs metụtara ọgwụgwọ (TRAEs) gụnyere ọrịa ntọhapụ cytokine, mmụba nrụgide intracranial (ICP), isi ọwụwa, epilepsy, mbelata ọkwa nke nsụhọ, ịgbọ agbọ, na pyrexia. Ọtụtụ TRAE bụ ọkwa nke 1-2, ebe a hụrụ TRAE atọ nke ọkwa nke 3: otu ikpe nke mmụba nke ICP na ọkwa nke 2, otu ikpe nke ọrịa epilepsy, na ikpe ọzọ nke mbelata ọkwa nke mmụọ na ọkwa nke 3. Dịka ọ dị na Jenụwarị 2024, ndị ọrịa isii sitere na ọkwa nke 1 na 2 ruru eru maka nyocha ndụ ọnwa 12; ọnụego nlanarị ọnwa 12 (OS) zuru oke bụ 83.3% (95% CI: 58.3% ~ 100%), na OS etiti bụ ọnwa 20.3 (95% CI: 20.3 ~ erughi). Mmadụ abụọ n'ime ndị ọrịa atọ sitere na ọkwa nke 2 nwetara nzaghachi nkebi na nke zuru oke, n'otu n'otu. Mgbe enyere CAR-T, a hụrụ mmụba dị ukwuu na cytokines, gụnyere IL-6 na IFN-γ, na ọnụọgụgụ ndị ọzọ nke mkpụrụ ndụ ihe nketa CAR na mmiri cerebrospinal, ebe a hụrụ naanị obere mmụba na ọbara dị n'akụkụ.
Mmechi: N'ime nnwale a, a na-ewere ọgwụgwọ rGBM na TX103 dị ka ihe dị mma ma na-anabata ya. Nsonaazụ nwa oge ndị a na-akwado ọmụmụ ihe ọzọ site na iji TX103 iji mee ka nsonaazụ ndụ dịkwuo mma na ndị ọrịa nwere rGBM.
Ugbu a, enwere ọtụtụ nnwale ụlọ ọgwụ CAR-T ndị ọzọ na China, ha na-achọkwa ndị ọrịa. Maka ndụmọdụ gbasara ọgwụ ọhụrụ na teknụzụ, ị nwere ike ịkpọtụrụ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region.
Nọmba ekwentị: 4008803716
Email：myimmnet@163.com
Oge ozi: Disemba-09-2024